Progress and Challenges in Pharmacogenomics

Affiliations

¹ Departments of Pediatrics and Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
² Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein, Campus Kiel, Germany.

Editorial

Sara L Van Driest et al. Clin Pharmacol Ther. 2021 Sep.

. 2021 Sep;110(3):529-532.

doi: 10.1002/cpt.2359.

¹ Departments of Pediatrics and Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
² Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein, Campus Kiel, Germany.

No abstract available

References

1. Deshpande, P. et al. Immunopharmacogenomics: mechanisms of HLA-associated drug reactions. Clin. Pharmacol. Ther. 110, 607-615 (2021).
1. Liu, Y. et al. Class II human leukocyte antigen variants associate with risk of pegaspargase hypersensitivity. Clin. Pharmacol. Ther. 110, 794-802 (2021).
1. Luzum, J.A., Petry, N., Taylor, A.K., Van Driest, S.L., Dunnenberger, H.M. & Cavallari, L.H. Moving pharmacogenetics into practice: it's all about the evidence! Clin. Pharmacol. Ther. 110, 649-661 (2021).
1. Whirl-Carrillo, M. et al. An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clin. Pharmacol. Ther. 110, 563-572 (2021).
1. Zanardi, R., Manfredi, E., Montrasio, C., Colombo, C., Serretti, A. & Fabbri, C. Pharmacogenetic-guided treatment of depression: real-world clinical applications, challenges and perspectives. Clin. Pharmacol. Ther. 110, 573-581 (2021).